We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Agilent, Singapore Institute Collaborate

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Agilent, Singapore Institute Collaborate "

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Aimed at bridging gaps in analytical tests and standards for glycoprotein-based drugs, the collaboration will further develop Agilent's AssayMAP Bravo platform, an automated platform for high-throughput protein sample preparation and purification. Combining the technology with mass spectrometry, BTI researchers will leverage their knowledge in the production of therapeutic glycoproteins to develop optimized workflows and methods for analyzing N- and O-linked glycans, the partners said. 

According to the partners, glycoproteins now comprise the majority of approved biopharmaceutical drugs, but current analytical methods for characterizing glycans are time-consuming and are difficult to deploy in commercial settings. Additionally, existing methods have limited abilities to detect and analyze minor glycan species. 

"Bringing together expertise from Agilent and BTI will allow us to develop an approach for [the] analysis of therapeutic glycoproteins that requires [less] user intervention while keeping to the high standards of analysis needed," Zhang Peiqing, a BTI research scientist and the lead investigator for the projects under the collaboration, said in a statement. 

BTI is a research institute of Singapore's Agency for Science, Technology and Research.